恶性肿瘤患者血清糖链抗原CA50水平及其临床意义

Clinical value of detecting serum carbohydrate antigen-50 in patients with malignant neolpasm

目的研究恶性肿瘤患者血清糖链抗原CA50表达水平及其临床意义。方法采用免疫放射分析法(IRMA)对88名正常人,69例良性疾病及160例恶性肿瘤患者进行血清CA50水平测定。结果恶性肿瘤患者血清CA50水平(31.8±23.4U/ml)显著高于正常人(8.6±5.7U/ml,P<0.0005),良性疾病患者血清CA50水平(10.1±6.1U/ml)与正常人相比较无显著性差异(P>0.05)。以20U/ml为阳性界值,大肠癌、胰腺癌、食管癌、胃癌、肝癌、乳腺癌、肺癌患者CA50阳性率显著高于正常人(P<0.005),良性疾病患者阳性率与正常人相比无显著性差异(P>0.05)。CA50对诊断恶性肿瘤的灵敏度为56.9%,特异性为95.5%,有效率为76.0%。结论CA50是一种有潜力的肿瘤标志物,具有较宽的恶性肿瘤识别谱,可作为恶性肿瘤诊断与鉴别诊断的辅助指标之一。

Objective To study on the level of carbohydrate antigen 50 (CA50) in serum of patients with malignant neoplasm and its clinical significance. Methods The serum CA50 levels were determined by immunoradiometric assay(IRMA)in 88 healthy controls,69 patients with benign disease and 160 cancer patients. Results The serum CA50 levels of patients with malignant neoplasm (31.8±23.4U/ml) were significantly higher than those of healthy controls (8.6±5.7U/ml, P<0.0005). There was no significant difference in serum CA50 levels between patients with benign disease (10.1±6.1U/ml) and healthy controls (P>0.05). Taking 20U/ml as positive limit, there were significant higher CA50 positive rate in patients with cancer of various types (colorectal, pancreatic, esophageai, gastric, liver, breast and lung cancer) (P<0.005), while no significant difference in patients with benign disease (P>0.05), as compared with that of healthy controls. The sensitivity, specificity and efficacy of CA50 for malignant neoplasm were 56.9%, 95.5%and 76.0%, respectively. Conclusions It is suggested that CA50, a potential tumor marker with wider spectrum of tumor identity, may be considered as one of the indicators in diagnosis and differential diagnosis of malignant neoplasm.